搜索
Codexis Inc
CDXS添加自选
2.470USD
+0.080+3.35%
收盘 07/02, 13:00（美东）报价延迟15分钟
222.99M总市值
亏损市盈率 TTM
关键数据
2.400今开
2.500最高
1.36M成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
1.50%换手率
2.390昨收
2.400最低
2.89M成交额
亏损市盈率静
5.79市净率
0.00%股息率 TTM
-24.77%ROA
3.87052周最高
1.82量比
-65.28M净利润
90.28M总股本
-0.3495每股收益TTM
2.50Beta
-68.90%ROE
0.95852周最低
4.18%振幅
86.46%毛利率
222.99M总市值
-3.23回报/风险
4.54%风险率
TradingKey Codexis Inc股票评分
单位: USD 更新时间: 2026-07-02操作建议
Codexis Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名78/387位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.58。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Codexis Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Codexis Inc亮点
亮点风险
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
业绩增长期
公司处于发展阶段，最新年度总收入70.39M美元
估值低估
公司最新PE估值-7.07，处于3年历史低位
机构减仓
最新机构持股66.34M股，环比减少17.31%
ETHSX持仓
明星投资者ETHSX持仓，最新持仓市值210.50K
分析师目标
根据
7
位分析师
买入
评级
6.583
目标均价
+175.45%
涨幅空间
Codexis Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Codexis Inc简介
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
公司代码CDXS
公司Codexis Inc
CEOMoore (Alison)
网址https://www.codexis.com/
相关品种
热门品种
常见问题
Codexis Inc(CDXS)的当前股价是多少？
Codexis Inc(CDXS)的当前股价是 2.47。
Codexis Inc的股票代码是什么？
Codexis Inc的股票代码是CDXS。
Codexis Inc股票的52周最高点是多少？
Codexis Inc股票的52周最高点是3.87。
Codexis Inc股票的52周最低点是多少？
Codexis Inc股票的52周最低点是0.96。
Codexis Inc的市值是多少？
Codexis Inc的市值是224.51M。
现在Codexis Inc(CDXS)的股票是买入、持有还是卖出？
根据分析师评级，Codexis Inc(CDXS)的总体评级为买入，目标价格为6.58。
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是多少
Codexis Inc(CDXS)股票的每股收益（EPS TTM）是-0.50。